{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:16:17Z","timestamp":1772165777879,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals, Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Retinal diseases, including wet or dry age-related macular degeneration, diabetic macular edema, and diabetic retinopathy (DR), are underdiagnosed and undertreated in the United States. Clinical trials support the effectiveness of anti-vascular endothelial growth factor (anti-VEGF) therapies for several retinal conditions, but real-world data suggest underuse by clinicians, resulting in patients experiencing poorer visual outcomes over time. Continuing education (CE) has demonstrated effectiveness at changing practice behaviors, but more research is needed to understand whether CE can help address diagnostic and treatment gaps.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This test and control matched pair analysis examined pre-\/post-test knowledge of retinal diseases and guideline-based screening and intervention among 10,786 healthcare practitioners (i.e., retina specialists, ophthalmologists, optometrists, primary care providers, diabetes educators, pharmacists\/managed care specialists, and other healthcare providers, such as registered nurses, nurse practitioners, and physician assistants) who participated in a modular, interactive CE initiative. An additional medical claims analysis provided data on practice change, evaluating use of VEGF-A inhibitors among retina specialist and ophthalmologist learners (n\u2009=\u20097,827) pre-\/post-education, compared to a matched control group of non-learners. Outcomes were pre-\/post-test change in knowledge\/competence and clinical change in application of anti-VEGF therapy, as identified by the medical claims analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Learners significantly improved knowledge\/competence scores on early identification and treatment, identifying patients who could benefit from anti-VEGF agents, using guideline-recommended care, recognizing the importance of screening and referral, and recognizing the importance of early detection and care for DR (all\n                      <jats:italic>P<\/jats:italic>\n                      -values\u2009=\u20090.003 to 0.004). Compared with matched controls, learners\u2019 incremental total injections for anti-VEGF agents for retinal conditions increased more after the CE intervention (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001); specifically, there were 18,513 more (new) anti-VEGF injections prescribed versus non-learners (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This modular, interactive, immersive CE initiative resulted in significant knowledge\/competence gains among retinal disease care providers and changes in practice-related treatment behaviors (i.e., appropriate consideration and greater incorporation of guideline-recommended anti-VEGF therapies) among participating ophthalmologists and retina specialists compared to matched controls. Future studies will utilize medical claims data to show longitudinal impact of this CE initiative on treatment behavior among specialists and impact on diagnosis and referral rates among optometrists and primary care providers who participate in future programming.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-023-03034-9","type":"journal-article","created":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T17:18:12Z","timestamp":1687454292000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of an immersive, interactive medical education initiative on guideline-based retinal disease management knowledge\/competence and effectual practice change"],"prefix":"10.1186","volume":"23","author":[{"given":"Rishi P.","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Welch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole L.","family":"Longo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt","family":"Frese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,22]]},"reference":[{"issue":"1","key":"3034_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3928\/23258160-20201223-06","volume":"52","author":"TR Rosenblatt","year":"2021","unstructured":"Rosenblatt TR, Vail D, Saroj N, Boucher N, Moshfeghi DM, Moshfeghi AA. Increasing incidence and prevalence of common retinal diseases in retina practices across the United States. Ophthalmic Surg Lasers Imaging Retina. 2021;52(1):29\u201336. https:\/\/doi.org\/10.3928\/23258160-20201223-06","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"3034_CR2","unstructured":"National Eye Institute. Visual impairment, blindness cases in U.S. expected to double by 2050. May 2016. https:\/\/www.nih.gov\/news-events\/news-releases\/visual-impairment-blindness-cases-us-expected-double-2050#:~:text=With%20the%20youngest%20of%20the,Eye%20Institute%2\u00a0C%20part%20of%20the."},{"issue":"1","key":"3034_CR3","doi-asserted-by":"publisher","first-page":"CD006543","DOI":"10.1002\/14651858.CD006543.pub2","volume":"1","author":"RM van Nispen","year":"2020","unstructured":"van Nispen RM, Virgili G, Hoeben M, Langelaan M, Klevering J, Keunen JE, et al. Low vision rehabilitation for better quality of life in visually impaired adults. Cochrane Database Syst Rev. 2020;1(1):CD006543. https:\/\/doi.org\/10.1002\/14651858.CD006543.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"3034_CR4","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1001\/jamaophthalmol.2021.0146","volume":"139","author":"L Assi","year":"2021","unstructured":"Assi L, Chamseddine F, Ibrahim P, Sabbagh H, Rosman L, Congdon N, et al. A global assessment of eye health and quality of life: a systematic review of systematic reviews. JAMA Ophthalmol. 2021;139(5):526\u201341. https:\/\/doi.org\/10.1001\/jamaophthalmol.2021.0146","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"3034_CR5","doi-asserted-by":"publisher","first-page":"100106","DOI":"10.1016\/j.xops.2021.100106","volume":"2","author":"D Schofield","year":"2022","unstructured":"Schofield D, Kraindler J, Tan O, Shrestha R, Jelovic D, West S, et al. Patient-reported health-related quality of life in individuals with inherited retinal Diseases. Ophthalmol Sci. 2022;2(1):100106. https:\/\/doi.org\/10.1016\/j.xops.2021.100106","journal-title":"Ophthalmol Sci"},{"issue":"1","key":"3034_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41687-017-0023-4","volume":"1","author":"M Prem Senthil","year":"2017","unstructured":"Prem Senthil M, Khadka J, Gilhotra JS, Simon S, Pesudovs K. Exploring the quality of life issues in people with retinal diseases: a qualitative study. J Patient Rep Outcomes. 2017;1(1):1\u20134. https:\/\/doi.org\/10.1186\/s41687-017-0023-4","journal-title":"J Patient Rep Outcomes"},{"issue":"6","key":"3034_CR7","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1001\/jamaophthalmol.2017.0830","volume":"135","author":"DC Neely","year":"2017","unstructured":"Neely DC, Bray KJ, Huisingh CE, Clark ME, McGwin G, Owsley C. Prevalence of undiagnosed age-related macular degeneration in primary eye care. JAMA Ophthalmol. 2017;135(6):570\u20135. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.0830","journal-title":"JAMA Ophthalmol"},{"key":"3034_CR8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3389\/fendo.2019.00843","volume":"10","author":"SH Sinclair","year":"2019","unstructured":"Sinclair SH, Schwartz SS. Diabetic retinopathy\u2013an underdiagnosed and undertreated inflammatory, neuro-vascular complication of diabetes. Front Endocrinol. 2019;10:843. https:\/\/doi.org\/10.3389\/fendo.2019.00843","journal-title":"Front Endocrinol"},{"issue":"16 Suppl","key":"3034_CR9","first-page":"311","volume":"25","author":"JM Coney","year":"2019","unstructured":"Coney JM. Addressing unmet needs in diabetic retinopathy. Am J Manag Care. 2019;25(16 Suppl):311\u20136.","journal-title":"Am J Manag Care"},{"issue":"1","key":"3034_CR10","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1016\/j.ophtha.2019.09.024","volume":"127","author":"CJ Flaxel","year":"2020","unstructured":"Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, et al. Age-related Macular Degeneration Preferred Practice Pattern. Ophthalmology. 2020a;127(1):P1\u2013P65. https:\/\/doi.org\/10.1016\/j.ophtha.2019.09.024","journal-title":"Ophthalmology"},{"issue":"3","key":"3034_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/2474126419834711","volume":"3","author":"SJ Bakri","year":"2019","unstructured":"Bakri SJ, Wolfe JD, Regillo CD, Flynn HW Jr, Wykoff CC. Evidence-based guidelines for management of diabetic macular edema. J VitreoRetinal Dis. 2019;3(3):145\u201352. https:\/\/doi.org\/10.1177\/2474126419834711","journal-title":"J VitreoRetinal Dis"},{"issue":"1","key":"3034_CR12","doi-asserted-by":"publisher","first-page":"P66","DOI":"10.1016\/j.ophtha.2019.09.025","volume":"127","author":"CJ Flaxel","year":"2020","unstructured":"Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, et al. Diabetic retinopathy preferred practice pattern. Ophthalmology. 2020b;127(1):P66\u2013145. https:\/\/doi.org\/10.1016\/j.ophtha.2019.09.025","journal-title":"Ophthalmology"},{"issue":"2","key":"3034_CR13","doi-asserted-by":"publisher","first-page":"P288","DOI":"10.1016\/j.ophtha.2019.09.029","volume":"127","author":"CJ Flaxel","year":"2020","unstructured":"Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, et al. Retinal vein occlusions preferred practice pattern. Ophthalmology. 2020c;127(2):P288\u2013320. https:\/\/doi.org\/10.1016\/j.ophtha.2019.09.029","journal-title":"Ophthalmology"},{"issue":"1","key":"3034_CR14","doi-asserted-by":"publisher","first-page":"e000398","DOI":"10.1136\/bmjophth-2019-000398","volume":"4","author":"S Khanna","year":"2019","unstructured":"Khanna S, Komati R, Eichenbaum DA, Hariprasad I, Ciulla TA, Hariprasad SM. Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. BMJ Open Ophthalmol. 2019;4(1):e000398. https:\/\/doi.org\/10.1136\/bmjophth-2019-000398","journal-title":"BMJ Open Ophthalmol"},{"key":"3034_CR15","unstructured":"Asahi MG, Dang M, Gallemore RP. Practical guidelines for RVO Management. Retina Today; 2014. https:\/\/retinatoday.com\/articles\/2014-july-aug\/practical-guidelines-for-rvo-management"},{"key":"3034_CR16","doi-asserted-by":"publisher","unstructured":"Jonas JB, Mones J, Glacet-Bernard A, Coscas G. Retinal Vein Occlusions. In: Coscas G, editor: Macular Edema. 2nd, revised and extended edition. Dev Ophthalmol. Basel, Karger, 2017, vol\u00a058, pp\u00a0139\u2013167. https:\/\/doi.org\/10.1159\/000455278","DOI":"10.1159\/000455278"},{"key":"3034_CR17","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3109\/08820538.2014.959198","volume":"29","author":"EK Deschler","year":"2014","unstructured":"Deschler EK, Sun JK, Silva PS. Side-effects and complications of laser treatment in diabetic retinal disease. Semin Ophthalmol. 2014;29:290\u2013300. https:\/\/doi.org\/10.3109\/08820538.2014.959198","journal-title":"Semin Ophthalmol"},{"key":"3034_CR18","unstructured":"Haynes J, Huddleston S, Rafieetary M, Anti. -VEGF in 2022: Innovation and Ambition. Review of Optometry. :text=The%20development%20of%20anti%2DVEGF,to%20better%20resolve%20retinal%20issues; March 2022. https:\/\/www.reviewofoptometry.com\/article\/antivegf-in-2022-innovation-and-ambition#:~"},{"key":"3034_CR19","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.ajo.2013.12.018","volume":"157","author":"NM Holekamp","year":"2014","unstructured":"Holekamp NM, Liu Y, Yeh W-S, Chia Y, Kiss S, Almony A, et al. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration. Am J Ophthalmol. 2014;157:825\u201333. https:\/\/doi.org\/10.1016\/j.ajo.2013.12.018","journal-title":"Am J Ophthalmol"},{"key":"3034_CR20","unstructured":"Berenberg T, Kiss S. Real-world utilization of anti-VEGF agents. Rev Opthamol. 2016. https:\/\/www.reviewofophthalmology.com\/article\/realworld-utilization-of-antivegf-agents"},{"issue":"1","key":"3034_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000502747","volume":"243","author":"J Mon\u00e9s","year":"2020","unstructured":"Mon\u00e9s J, Singh RP, Bandello F, Souied E, Liu X, Gale R. Undertreatment of neovascular age-related macular degeneration after 10 years of anti-vascular endothelial growth factor therapy in the real world: the need for a change of mindset. Ophthalmologica. 2020;243(1):1\u20138. https:\/\/doi.org\/10.1159\/000502747","journal-title":"Ophthalmologica"},{"key":"3034_CR22","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2015","unstructured":"Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99:220\u20136. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305327","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"3034_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","volume":"4","author":"TA Ciulla","year":"2020","unstructured":"Ciulla TA, Hussain RM, Pollack JS, Williams D. Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in Neovascular AMD Patients: a \u201cReal World\u201d analysis in 49,485 eyes. Ophthalmol Retina. 2020;4(1):19\u201330. https:\/\/doi.org\/10.1016\/j.oret.2019.05.017","journal-title":"Ophthalmol Retina"},{"issue":"12","key":"3034_CR24","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.oret.2018.06.004","volume":"2","author":"TA Ciulla","year":"2019","unstructured":"Ciulla TA, Bracha P, Pollack J, Williams DF. Real-world outcomes of anti\u2013vascular endothelial growth factor therapy in diabetic macular edema in the United States. Ophthalmol Retina. 2019;2(12):1179\u201387. https:\/\/doi.org\/10.1016\/j.oret.2018.06.004","journal-title":"Ophthalmol Retina"},{"key":"3034_CR25","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.ophtha.2017.10.010","volume":"125","author":"P Rao","year":"2018","unstructured":"Rao P, Lum F, Wood K, Salman C, Burugapalli B, Hall R, et al. Real-world vision in age-related macular degeneration patients treated with single Anti\u2013VEGF drug type for 1 year in the iris registry. Ophthalmol. 2018;125:522\u20138. https:\/\/doi.org\/10.1016\/j.ophtha.2017.10.010","journal-title":"Ophthalmol"},{"key":"3034_CR26","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2147\/OPTH.S231913","volume":"16","author":"CS Tan","year":"2022","unstructured":"Tan CS, Ngo WK, Chay IW, Ting DS, Sadda SR. Neovascular age-related Macular Degeneration (nAMD): a review of Emerging Treatment Options. Clin Ophthalmol. 2022;16:917. https:\/\/doi.org\/10.2147\/OPTH.S231913","journal-title":"Clin Ophthalmol"},{"key":"3034_CR27","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.ophtha.2013.11.031","volume":"121","author":"Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group","year":"2014","unstructured":"Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group. The Neovascular Age-Related Macular Degeneration Database: Multicenter Study of 92976 ranibizumab injections. Ophthalmol. 2014;121:1092\u2013101.","journal-title":"Ophthalmol"},{"issue":"9","key":"3034_CR28","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1080\/0142159X.2019.1615608","volume":"41","author":"S Ramani","year":"2019","unstructured":"Ramani S, McMahon GT, Armstrong EG. Continuing professional development to foster behaviour change: from principles to practice in health professions education. Med Teach. 2019;41(9):1045\u201352. https:\/\/doi.org\/10.1080\/0142159X.2019.1615608","journal-title":"Med Teach"},{"issue":"2","key":"3034_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/chp.21290","volume":"35","author":"RM Cervero","year":"2015","unstructured":"Cervero RM, Gaines JK. The impact of CME on physician performance and patient health outcomes: an updated synthesis of systematic reviews. J Contin Ed Health Prof. 2015;35(2):131\u20138. https:\/\/doi.org\/10.1002\/chp.21290","journal-title":"J Contin Ed Health Prof"},{"issue":"11","key":"3034_CR30","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/OPX.0000000000001595","volume":"97","author":"CM Maatouk","year":"2020","unstructured":"Maatouk CM, Hentati F, Urbano CA, Greenlee TE, Conti TF, Hom GL, et al. Effects of quality improvement education in diabetic retinopathy on routine clinical practice patterns of optometrists. Optom Vis Sci. 2020;97(11):936\u201343. https:\/\/doi.org\/10.1097\/OPX.0000000000001595","journal-title":"Optom Vis Sci"},{"key":"3034_CR31","unstructured":"Longo NL, Welch LK, Frese M. Leveraging the Technological Advances of Virtual Reality (VR) to Foster Engaging and Interactive Learning, Ultimately Impacting Patient Quality of Care. American College of Osteopathic Internists (ACOI) 2022. Baltimore, MD; October 19\u201322, 2022. Poster presentation 236."},{"issue":"1","key":"3034_CR32","first-page":"75","volume":"21","author":"F Mostofian","year":"2015","unstructured":"Mostofian F, Ruban C, Simunovic N, Bhandari M. Changing physician behavior: what works. Am J Manag Care. 2015;21(1):75\u201384.","journal-title":"Am J Manag Care"},{"issue":"1086","key":"3034_CR33","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1136\/postgradmedj-2015-133662","volume":"92","author":"L VanNieuwenborg","year":"2016","unstructured":"VanNieuwenborg L, Goossens M, De Lepeleire J, Schoenmakers B. Continuing medical education for general practitioners: a practice format. Postgrad Med J. 2016;92(1086):217\u201322.","journal-title":"Postgrad Med J"},{"issue":"1","key":"3034_CR34","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/chp.88","volume":"27","author":"M Mansouri","year":"2007","unstructured":"Mansouri M, Lockyer J. A meta-analysis of continuing medical education effectiveness. J Continue Edu Health Professions. 2007;27(1):6\u201315.","journal-title":"J Continue Edu Health Professions"},{"key":"3034_CR35","unstructured":"Frese M, Gallow C, Grzybowski A, Welch L, Rasulnia M. Using Virtual Technology to Advance CME\u2019s Role in Today\u2019s Healthcare Environment. 2016. https:\/\/www.medlearninggroup.com\/wp-content\/uploads\/2016\/12\/Using-VIRTUAL-TECHNOLOGY-to-Advance-CMEs-Role-in-Todays-Healthcare-Envir\u2026 pdf."},{"issue":"8","key":"3034_CR36","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.3390\/pharmaceutics13081137","volume":"13","author":"I Chatziralli","year":"2021","unstructured":"Chatziralli I, Loewenstein A. Intravitreal anti-vascular endothelial growth factor agents for the treatment of diabetic retinopathy: a review of the literature. Pharmaceutics. 2021;13(8):1137. https:\/\/doi.org\/10.3390\/pharmaceutics13081137","journal-title":"Pharmaceutics"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-023-03034-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-023-03034-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-023-03034-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T17:18:27Z","timestamp":1687454307000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-023-03034-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3034"],"URL":"https:\/\/doi.org\/10.1186\/s12886-023-03034-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2565067\/v1","asserted-by":"object"}]},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,22]]},"assertion":[{"value":"8 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data was collected as part of an observational retrospective review. All data used in the study was de-identified. Study participants provided informed consent to participate in the research. As per guidelines from the U.S. Department of Health and Human Services on Protection of Human Research Subjects\u2014sections (d) (2) (i) and (ii) and (d) (4) (i) and (ii) of 46.104 Exempt Research\u2014this study meets criteria for Exempt Research; thus, Institutional Review Board approval was not needed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all subjects and\/or their legal guardian(s) for publication of identifying information\/images in an online open-access publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RPS has received personal fees from Genentech\/Roche; Alcon\/Novartis; Zeiss; Bausch + Lomb; Regeneron Pharmaceuticals, Inc; Gyroscope; and Asceplix. RPS has received grant funding from Apellis and Graybug. LW, NLL, and MF are employees of Med Learning Group.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"285"}}